Literature DB >> 31676899

Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test-Variability Between Immunoassay and HPLC-MS/MS.

Moe Thuzar1,2, Karen Young3, Ashraf H Ahmed1, Greg Ward3, Martin Wolley1, Zeng Guo1, Richard D Gordon1, Brett C McWhinney4, Jacobus P Ungerer4,5, Michael Stowasser1.   

Abstract

BACKGROUND: In primary aldosteronism (PA), excessive, autonomous secretion of aldosterone is not suppressed by salt loading or fludrocortisone. For seated saline suppression testing (SSST), the recommended diagnostic cutoff 4-hour plasma aldosterone concentration (PAC) measured by high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS is 162 pmol/L. Most diagnostic laboratories, however, use immunoassays to measure PAC. The cutoff for SSST using immunoassay is not known. We hypothesized that the cutoff is different between the assays.
METHODS: We analyzed 80 of the 87 SSST tests that were performed during our recent study defining the HPLC-MS/MS cutoff. PA was confirmed in 65 by positive fludrocortisone suppression testing (FST) and/or lateralization on adrenal venous sampling and excluded in 15 by negative FST. PAC was measured by a chemiluminescence immunoassay (PACIA) in the SSST samples using the DiaSorin Liaison XL analyzer, and receiver operating characteristics (ROC) analysis was performed to identify the PACIA cutoff.
RESULTS: ROC revealed good performance (area under the curve = 0.893; P < .001) of 4-hour postsaline PACIA for diagnosis of PA and an optimal diagnostic cutoff of 171 pmol/L, with sensitivity and specificity of 95.4% and 80.0%, respectively. A higher cutoff of 217 pmol/L improved specificity (86.7%) with lower sensitivity (86.2%). PACIA measurements strongly correlated with PAC measured by HPLC-MS (r = 0.94, P < .001).
CONCLUSIONS: A higher diagnostic cutoff for SSST should be employed when PAC is measured by immunoassay rather than HPLC-MS/MS. The results suggest that (i) PA can be excluded if 4-hour PACIA is less than 171 pmol/L, and (ii) PA is highly likely if the PACIA is greater than 217 pmol/L by chemiluminescence immunoassay. A gray zone exists between the cutoffs of 171 and 217 pmol/L, likely reflecting a lower specificity of immunoassay. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  confirmation; diagnosis; hyperaldosteronism; immunoassay; primary aldosteronism; seated saline suppression test

Mesh:

Substances:

Year:  2020        PMID: 31676899     DOI: 10.1210/clinem/dgz150

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Acute Intravenous NaCl and Volume Expansion Reduces Sodium-Chloride Cotransporter Abundance and Phosphorylation in Urinary Extracellular Vesicles.

Authors:  Aihua Wu; Martin J Wolley; Qi Wu; Diane Cowley; Johan Palmfeldt; Paul A Welling; Robert A Fenton; Michael Stowasser
Journal:  Kidney360       Date:  2022-03-01

Review 2.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

3.  Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.

Authors:  Alexander A Leung; Christopher J Symonds; Gregory L Hundemer; Paul E Ronksley; Diane L Lorenzetti; Janice L Pasieka; Adrian Harvey; Gregory A Kline
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

4.  Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions.

Authors:  Jenifer M Brown; Richard J Auchus; Brooke Honzel; James M Luther; Nicholas Yozamp; Anand Vaidya
Journal:  J Endocr Soc       Date:  2022-03-23

5.  Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection.

Authors:  Nicholas Yozamp; Gregory L Hundemer; Marwan Moussa; Jonathan Underhill; Tali Fudim; Barry Sacks; Anand Vaidya
Journal:  Hypertension       Date:  2020-12-07       Impact factor: 10.190

6.  The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy.

Authors:  Graeme Eisenhofer; Max Kurlbaum; Mirko Peitzsch; Georgiana Constantinescu; Hanna Remde; Manuel Schulze; Denise Kaden; Lisa Marie Müller; Carmina T Fuss; Sonja Kunz; Sylwia Kołodziejczyk-Kruk; Sven Gruber; Aleksander Prejbisz; Felix Beuschlein; Tracy Ann Williams; Martin Reincke; Jacques W M Lenders; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

7.  Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion.

Authors:  Yoshinori Ozeki; Mizuki Kinoshita; Shotaro Miyamoto; Yuichi Yoshida; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Kengo Kambara; Hirotaka Shibata
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

8.  Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.

Authors:  Eugene Merzon; Dmitry Tworowski; Alessandro Gorohovski; Shlomo Vinker; Avivit Golan Cohen; Ilan Green; Milana Frenkel-Morgenstern
Journal:  FEBS J       Date:  2020-08-28       Impact factor: 5.622

9.  Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS.

Authors:  Carmina Teresa Fuss; Katharina Brohm; Max Kurlbaum; Anke Hannemann; Sabine Kendl; Martin Fassnacht; Timo Deutschbein; Stefanie Hahner; Matthias Kroiss
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

10.  Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.

Authors:  Yen Kheng Tan; Yu Heng Kwan; David Choon Liang Teo; Marieke Velema; Jaap Deinum; Pei Ting Tan; Meifen Zhang; Joan Joo Ching Khoo; Wann Jia Loh; Linsey Gani; Thomas F J King; Eberta Jun Hui Tan; Shui Boon Soh; Vanessa Shu Chuan Au; Tunn Lin Tay; Lily Mae Quevedo Dacay; Keng Sin Ng; Kang Min Wong; Andrew Siang Yih Wong; Foo Cheong Ng; Tar Choon Aw; Yvonne Hui Bin Chan; Khim Leng Tong; Sheldon Shao Guang Lee; Siang Chew Chai; Troy Hai Kiat Puar
Journal:  Endocr Connect       Date:  2021-07-26       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.